Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXI-001 with Decitabine and Lymphodepletion for Relapsed/Refractory AML or MDS Post-HCT
NCT06572631Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of NEXI-001 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 1.5 years and Dose limiting toxicity. Planned start Jun 2025; status: withdrawn.
02
Drugs
NEXI-001
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06572631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572631.